Retatrutide Benefits: What the Clinical Research Actually Shows (2026)
Retatrutide (Eli Lilly, LY3437943) is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors. Most summaries of retatrutide benefits lead with one headline number (roughly 24 percent body weight lost) and stop there. The fuller research picture is more useful: retatrutide is a single peptide that hits three metabolic receptors at once, and its phase 2 human data span obesity, type 2 diabetes, and fatty liver disease. It is also still investigational, not an approved medicine.
The Compound Universe Take: Retatrutide (Eli Lilly, LY3437943) is a once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors. In a phase 2 obesity trial, the 12 mg dose produced a mean weight reduction of about 24 percent at 48 weeks (Human, phase 2). Separate phase 2 trials showed improved blood sugar in type 2 diabetes and large reductions in liver fat. As of 2026 it remains in phase 3 and is not FDA-approved.
New here? Start with the peptides for weight loss overview for the wider field, then use this page for retatrutide specifically.
What is retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly under the code name LY3437943. Unlike single-target incretin drugs, it activates three receptors that govern appetite, insulin, and energy use: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor [4].
That triple design is the whole point. Semaglutide targets one receptor (GLP-1); tirzepatide targets two (GIP and GLP-1); retatrutide adds glucagon-receptor activity, which is linked to higher energy expenditure and fat metabolism [4].
The table below sets the baseline facts before the mechanism and trial detail.
| Attribute | Detail |
|---|---|
| Drug class | Triple hormone-receptor agonist (GIP / GLP-1 / glucagon) |
| Developer / code | Eli Lilly (LY3437943) |
| Most studied for | Obesity, type 2 diabetes, fatty liver (MASLD) |
| Highest evidence tier | Human, phase 2 randomized controlled trials |
| Regulatory status (US) | Investigational; in phase 3; not FDA-approved |
How retatrutide works: the triple agonist mechanism
The three receptor targets pull in the same metabolic direction through different levers.
GLP-1 activation slows gastric emptying and reduces appetite, the same route behind semaglutide. GIP activation supports glucose-dependent insulin secretion, sharpening the postprandial insulin response [4].
The glucagon arm is what separates retatrutide from tirzepatide. Glucagon-receptor agonism can raise energy expenditure and promote hepatic fat breakdown, which researchers propose explains both the size of the weight loss and the steep drop in liver fat seen in trials [4][6].
One honest caveat on mechanism: much of the receptor-level pharmacology comes from preclinical and early human work, and the long-term metabolic consequences of chronic glucagon-receptor activation are still being studied [6].
Retatrutide benefits in clinical trials
Retatrutide is unusual among “peptides” discussed in the wellness space because its evidence is genuinely human and randomized, not animal-only. Three phase 2 trials anchor the record.
Weight loss: the phase 2 obesity trial
The pivotal phase 2 obesity trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity or overweight and no diabetes over 48 weeks (Human, phase 2) [1].
At 48 weeks, mean weight change was -8.7 percent (1 mg), -22.8 percent (8 mg), and -24.2 percent (12 mg), versus -2.1 percent for placebo. At the 12 mg dose, 93 percent of participants lost at least 10 percent of body weight and 83 percent lost at least 15 percent [1].
Gastrointestinal side effects (nausea, diarrhea) were the most common, dose-related, and mostly mild to moderate. A dose-dependent rise in heart rate peaked around 24 weeks and then declined [1].
Blood sugar: the type 2 diabetes trial
A parallel phase 2 trial in people with type 2 diabetes (Rosenstock et al., Lancet 2023) tested retatrutide against placebo and an active comparator (Human, phase 2) [2].
Retatrutide produced clinically meaningful reductions in HbA1c and substantial weight loss, with a safety profile consistent with existing GLP-1 and GIP/GLP-1 receptor agonists [2]. The trial supports a metabolic benefit beyond weight alone, though it was a mid-stage study, not a cardiovascular outcomes trial.
Liver fat: the fatty liver (MASLD) trial
A phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nature Medicine 2024) measured liver fat directly by MRI (Human, phase 2a) [3].
At 24 weeks, relative liver fat fell about 82 percent at the 12 mg dose versus a slight increase on placebo, and 86 percent of participants at that dose reached normal liver fat (under 5 percent) [3]. The authors described the effect as among the largest reported in MASLD research to date, while noting it was a small, short trial.
Read this before the hype: Retatrutide is an investigational drug that has not completed phase 3 and is not FDA-approved. Products sold online as “retatrutide” are marketed “for research use only” and are not quality-controlled medicines. This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use.
Legal and regulatory status: is retatrutide FDA-approved?
As of mid-2026, retatrutide is not approved by the FDA or any major regulator [5]. It is in phase 3 development under Eli Lilly’s TRIUMPH and TRANSCEND trial programs, with regulatory filing anticipated after those readouts, not before [5].
That status matters for how the evidence is read. Every efficacy figure above comes from company-sponsored phase 2 trials; phase 3 confirmation and long-term safety data are still pending. Material sold outside clinical trials is unapproved and, in the US, falls under a “research use only” label rather than a prescription pathway.
| Research area | Key finding | Evidence tier | Status |
|---|---|---|---|
| Obesity | ~24% mean weight loss at 48 weeks (12 mg) | Human phase 2 | Phase 3 ongoing |
| Type 2 diabetes | HbA1c reduction plus weight loss | Human phase 2 | Phase 3 ongoing |
| Fatty liver (MASLD) | ~82% relative liver-fat reduction (12 mg) | Human phase 2a | Investigational |
| Mechanism | Triple GIP/GLP-1/glucagon agonism | Preclinical + human | Not FDA-approved |
Key takeaways
- Retatrutide benefits center on metabolism, driven by its triple agonism of the GIP, GLP-1, and glucagon receptors [4].
- The 12 mg dose produced about 24 percent mean weight loss at 48 weeks in a phase 2 obesity trial (Human, phase 2) [1].
- In type 2 diabetes, retatrutide lowered HbA1c alongside significant weight reduction in a phase 2 trial [2].
- A MASLD phase 2a trial showed roughly 82 percent relative liver-fat reduction at the top dose, among the largest such effects reported [3].
- Retatrutide is investigational and not FDA-approved; all current data are phase 2, with phase 3 trials still running [5].
Frequently asked questions
What are the main benefits of retatrutide?
In phase 2 trials, retatrutide produced large weight loss, improved blood sugar in type 2 diabetes, and sharply reduced liver fat. All of this is mid-stage human evidence, not yet confirmed in phase 3.
How is retatrutide different from tirzepatide?
Tirzepatide activates two receptors (GIP and GLP-1). Retatrutide adds a third, the glucagon receptor, which is linked to higher energy expenditure and may explain its larger weight and liver-fat effects.
How much weight did people lose on retatrutide?
In the phase 2 obesity trial, the 12 mg dose produced a mean reduction of about 24 percent of body weight at 48 weeks, compared with about 2 percent on placebo.
Is retatrutide FDA-approved?
No. As of 2026 retatrutide is investigational and in phase 3 trials. It has not been approved by the FDA or other major regulators.
Is retatrutide safe?
Phase 2 trials reported mostly mild-to-moderate gastrointestinal side effects and a temporary rise in heart rate. Long-term safety has not been established, since phase 3 data are still pending.
Can you buy retatrutide legally?
It is not available as an approved prescription medicine. Vials sold online are labeled “for research use only,” are unapproved, and are not quality-controlled for human use.
Retatrutide sits at the frontier of incretin-based metabolic medicine, where a single peptide (Eli Lilly’s LY3437943) engages the GIP, GLP-1, and glucagon receptors to influence appetite, insulin secretion, energy expenditure, and hepatic fat, extending the mechanism pioneered by semaglutide and tirzepatide; Compound Universe Genome tracks retatrutide against the primary phase 2 literature in obesity, type 2 diabetes, and MASLD so the summary reflects trial evidence and regulatory stage rather than marketing claims.
Read the research honestly and the retatrutide benefits look real but preliminary: strong phase 2 signals across weight, glucose, and liver fat, paired with an investigational status that keeps this a research compound rather than a proven, approved therapy until phase 3 results and regulators say otherwise.
Compare next: retatrutide vs tirzepatide | tirzepatide research summary | are peptides legal?
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315 / DOI 10.1056/NEJMoa2301972.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10401):529-544. PMID 37385280 / DOI 10.1016/S0140-6736(23)01053-X.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMID 38858523 / DOI 10.1038/s41591-024-03018-2.
- Retatrutide – A Game Changer in Obesity Pharmacotherapy (review of triple-agonist mechanism and trials). PMC12190491.
- Retatrutide development status: phase 3 (TRIUMPH / TRANSCEND programs), not FDA-approved as of 2026. ClinicalTrials.gov NCT05929079; Drugs.com drug history record.
- Sanyal AJ, et al. (mechanism discussion of glucagon-receptor agonism and hepatic fat), Nat Med. 2024. PMID 38858523.